pharma · Melanoma · Tumor · NKTR
Nektar Therapeutics UK
Nektar Therapeutics UK Limited
Nektar Therapeutics is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker NKTR. Primary therapeutic focus areas include Melanoma, Tumor, Renal Cell Carcinoma, Alopecia Areata, Pneum
455 Mission Bay Boulevard South, San Francisco, California 94158, US HQ
1990 Founded
610 Employees
Public company Type
NKTR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 455 Mission Bay Boulevard South, San Francisco, California 94158, US
- Founded
- 1990
- Employees
- 610
- Programs
- 57
- Drugs
- 31
- Patents
- 423
Pegylated Irinotecan
Phase 2 · small molecule · Stage IV Non-small Cell Lung Cancer (NSCLC)
Pegylated Irinotecan for Stage IV Non-small Cell Lung Cancer (NSCLC) is a Phase 2 program (small_molecule) at Nektar Therapeutics UK Limited with 1 ClinicalTrials.gov record(s).
Internal code IRB-30982
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nektar Therapeutics UK Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Stage IV Non-small Cell Lung Cancer (NSCLC)
- Status
- completed
- Trials
- 1